Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-11 · 1879 (6) · 189212
DOI: 10.1016/j.bbcan.2024.189212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-11. Verfasst von Yu He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 195 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer drug resistance is a major obstacle to the effectiveness of chemoradiotherapy, targeted therapy, and immunotherapy. CRISPR/Cas9 library screening has emerged as a powerful genetic screening tool with significant potential to address this challenge. This review provides an overview of the development, methodologies, and applications of CRISPR/Cas9 library screening in the study of cancer drug resistance. We explore its role in elucidating resistance mechanisms, identifying novel anticancer targets, and optimizing treatment strategies. The use of in vivo single-cell CRISPR screens is also highlighted for their capacity to reveal T-cell regulatory networks in cancer immunotherapy. Challenges in clinical translation are discussed, including off-target effects, complexities in data interpretation, and model selection. Despite these obstacles, continuous technological advancements indicate a promising future for CRISPR/Cas9 library screening in overcoming cancer drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, Y., Li, H., Ju, X., & Gong, B. (2024). Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(6), 189212. https://doi.org/10.1016/j.bbcan.2024.189212
Vancouver
He Y, Li H, Ju X, Gong B. Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189212. doi:10.1016/j.bbcan.2024.189212
BibTeX
@article{He2024,
author = {He, Yu and Li, Huan and Ju, Xueming and Gong, Bo},
title = {Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {6},
pages = {189212},
doi = {10.1016/j.bbcan.2024.189212}
}
EUVIMED